- Conditions
- Ganglioneuroblastoma, Recurrent Neuroblastoma
- Interventions
- Dinutuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Sargramostim, Temozolomide, Temsirolimus
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 136
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Downey, California + 106 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 8,144
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis
- Interventions
- Debamestrocel - MSC-NTF (NurOwn), Placebo
- Biological
- Lead sponsor
- Brainstorm-Cell Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more
- Conditions
- Substance Use
- Interventions
- Motivational Interviewing
- Behavioral
- Lead sponsor
- RTI International
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 827 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Claremont, California • Irvine, California + 32 more
- Conditions
- Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
- Interventions
- AR882 50 mg, AR882 75 mg, Placebo
- Drug
- Lead sponsor
- Arthrosi Therapeutics
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 818 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 52
- States / cities
- Foley, Alabama • Anchorage, Alaska • Peoria, Arizona + 47 more
- Conditions
- NYHA Class III Heart Failure, NYHA Class IV Heart Failure
- Interventions
- Optimizer System, No intervention: Optimal medical therapy
- Device · Other
- Lead sponsor
- Impulse Dynamics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 32
- States / cities
- Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 26 more
- Conditions
- Healthy
- Interventions
- IVX-A12, Placebo
- Biological
- Lead sponsor
- Icosavax, Inc.
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 10
- States / cities
- Tempe, Arizona • Hollywood, Florida • Stockbridge, Georgia + 7 more
- Conditions
- Major Depressive Disorder
- Interventions
- BMS-986511, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 18 more
- Conditions
- Bacterial Vaginosis
- Interventions
- 0.5% SPL7013 Gel, 1.0% SPL7013 Gel, 3.0% SPL7013 Gel, Placebo Gel
- Drug · Other
- Lead sponsor
- Starpharma Pty Ltd
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Denver, Colorado • Las Vegas, Nevada + 2 more
- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy, Macular Degeneration, Retinal Disease, Retinal Degeneration
- Interventions
- GEM103
- Biological
- Lead sponsor
- Gemini Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 8 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- tiotropium 18 mcg, tiotropium 1.25 mcg (2 actuations/day), tiotropium 2.5 mcg (2 actuations/day)
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 17,183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 303
- States / cities
- Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 243 more
- Conditions
- Cervical Cancer
- Interventions
- cisplatin, adjuvant therapy, conventional surgery, brachytherapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 43 more
- Conditions
- Dermatomyositis
- Interventions
- PF-06823859 low, Placebo Arm, PF-06823859 high
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 17 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Interventions
- Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,059 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 221
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Brolucizumab, Aflibercept
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 566 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 33 more
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane, Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Glendale, California • Long Beach, California + 27 more
- Conditions
- Psoriasis
- Interventions
- BI 695501, Humira
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Santa Ana, California + 11 more
- Conditions
- SARS-CoV-2 Infection, COVID-19
- Interventions
- BNT162b1, BNT162b2, Placebo, BNT162b2SA
- Biological · Other
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 46,969 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 154
- States / cities
- Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 106 more
- Conditions
- Dry Macular Degeneration, Geographic Atrophy
- Interventions
- CPCB-RPE1
- Biological
- Lead sponsor
- Regenerative Patch Technologies, LLC
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 3 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Placebo, LFG316
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Winter Haven, Florida • Cleveland, Ohio
- Conditions
- Kidney Cancer
- Interventions
- dactinomycin, filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 0 Years to 15 Years
- Enrollment
- 3,031 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2003
- U.S. locations
- 206
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
- Conditions
- HCV Infection
- Interventions
- ACH-0137171
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • La Jolla, California • San Francisco, California + 4 more
- Conditions
- Chronic Migraine
- Interventions
- Atogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 29
- States / cities
- Hoover, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
- Conditions
- Parkinson's Disease
- Interventions
- Minzasolmin (UCB0599)
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 40 Years to 78 Years
- Enrollment
- 428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 41
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Fresno, California + 35 more
- Conditions
- Mixed Hearing Loss, Single-Sided Deafness, Conductive Hearing Loss
- Interventions
- Osia 2 System
- Device
- Lead sponsor
- Cochlear
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Palo Alto, California • San Diego, California + 4 more